Short Communication Factors Influencing Time to CD4+ T Cell Counts >200 Cells/mm3 in HIV-Infected Individuals with CD4+ T Cell <50 Cells/mm3 at the Time of Starting Combination Antiretroviral Therapy

被引：0
|
作者：
Ku, Nam Su
Song, Young Goo
Han, Sang Hoon
Kim, Sun Bean
Kim, Hye-won
Jeong, Su Jin
Kim, Chang Oh
Kim, June Myung
Choi, Jun Yong [1 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2012年 / 28卷 / 12期
基金：
新加坡国家研究基金会;
关键词：
MEDICINE ASSOCIATION; DISEASES SOCIETY; VIRAL LOAD; VIRUS; DIAGNOSIS; AIDS; RECOMMENDATIONS; DETERMINANTS; TUBERCULOSIS; PROGRESSION;
D O I：
10.1089/aid.2011.0282
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We evaluated factors influencing time to CD4(+) T cell counts >200 cells/mm(3) in HIV-infected individuals with CD4(+) T cell <50 cells/mm(3) starting combination antiretroviral therapy (cART). We included a total of 29 patients on successful cART for more than 1 year. In a logistic regression model, higher pre-cART CD4(+) T cell counts were significantly associated with shorter time to CD4(+) T cell counts >200cells/mm(3) in HIV-infected individuals with baseline CD4(+) T cell <50 cells/mm(3). In survival analysis, patients having higher pre-cART CD4(+) T cell counts, especially 40-49 cells/mm(3), were at significantly higher risk of achieving CD4(+) T cell counts >200 cells/mm(3).
引用
收藏
页码：1594 / 1597
页数：4
相关论文
共 50 条
  • [1] Effects of Antiretroviral Therapy on Immune Function of HIV-infected Adults with Pulmonary Tuberculosis and CD4+ &gt;350 Cells/mm3
    Lancioni, Christina L.
    Mahan, C. Scott
    Johnson, Denise F.
    Walusimbi, Maria
    Chervenak, Keith A.
    Nalukwago, Sophie
    Charlebois, Edwin
    Havlir, Diane
    Mayanja-Kizza, Harriet
    Whalen, Christopher C.
    Boom, W. Henry
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (07) : 992 - 1001
  • [2] CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+T-cell counts &gt;200 cells/mm3
    Guiguet, Marguerite
    Kendjo, Eric
    Carcelain, Guislaine
    Abgrall, Sophie
    Mary-Krause, Murielle
    Tattevin, Pierre
    Yazdanpanah, Yazdan
    Cotagliola, Dominique
    Duval, Xavier
    ANTIVIRAL THERAPY, 2009, 14 (03) : 451 - 457
  • [3] The prevalence of HIV-infected patients with virological suppression but a CD4+ T- cell count of ≤ 200 cells/mm3 after highly active antiretroviral therapy initiation: A meta-analysis
    Wu, Zhihui
    Yang, Chunling
    Ma, Yuqing
    Wang, Yueyuan
    Zhang, Zhenkui
    Liu, Zhibin
    Li, Pengyu
    Guo, Huijun
    Jin, Yantao
    AIDS REVIEWS, 2022, 24 (01) : 16 - 23
  • [4] Increased IL-8 levels in HIV-infected individuals who initiated ART with CD4+ T cell counts &lt;350 cells/mm3 - A potential hallmark of chronic inflammation
    Ellwanger, Joel Henrique
    Valverde-Villegas, Jacqueline Maria
    Kaminski, Valeria de Lima
    de Medeiros, Rubia Marilia
    de Matos Almeida, Sabrina Esteves
    Santos, Breno Riegel
    de Melo, Marineide Goncalves
    Hackenhaar, Fernanda Schafer
    Bogo Chies, Jose Artur
    MICROBES AND INFECTION, 2020, 22 (09) : 474 - 480
  • [5] The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts &gt;350 cells/mm3
    Churchyard, Gavin John
    Snowden, Margaret Ann
    Hokey, David
    Dheenadhayalan, Veerabadran
    McClain, J. Bruce
    Douoguih, Macaya
    Pau, Maria Grazia
    Sadoff, Jerry
    Landry, Bernard
    VACCINE, 2015, 33 (15) : 1890 - 1896
  • [6] Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count &lt;200 cells/mm3
    Sidhu, Vaninder K.
    Foisy, Michelle M.
    Hughes, Christine A.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (12) : 1343 - 1348
  • [7] Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm3
    Simon Mutembo
    Jane N. Mutanga
    Kebby Musokotwane
    Lutangu Alisheke
    Christopher C. Whalen
    BMC Infectious Diseases, 16
  • [8] Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds &lt;200, &lt;350, and &lt;500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines
    Lodi, Sara
    Phillips, Andrew
    Touloumi, Giota
    Geskus, Ronald
    Meyer, Laurence
    Thiebaut, Rodolphe
    Pantazis, Nikos
    del Amo, Julia
    Johnson, Anne M.
    Babiker, Abdel
    Porter, Kholoud
    CLINICAL INFECTIOUS DISEASES, 2011, 53 (08) : 817 - 825
  • [9] Valganciclovir Reduces T Cell Activation in HIV-infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy
    Hunt, Peter W.
    Martin, Jeffrey N.
    Sinclair, Elizabeth
    Epling, Lorrie
    Teague, Juli
    Jacobson, Mark A.
    Tracy, Russell P.
    Corey, Lawrence
    Deeks, Steven G.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (10) : 1474 - 1483
  • [10] Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts &gt; 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial
    Boatman, Jeffrey A.
    Baker, Jason V.
    Emery, Sean
    Furrer, Hansjakob
    Mushatt, David M.
    Sedlacek, Dalibor
    Lundgren, Jens D.
    Neaton, James D.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 (01) : 10 - 17
12345